Figure 4.

Percent of the total treatment effect of direct and indirect effects contributing to change in the negative factor score at end point, all paliperidone ER doses combined (Canuso et al 2006a). The Path analysis results suggest a 33% direct effect of the combined paliperidone groups over placebo on the negative symptom factor score. Among those domains studied, the path analysis showed that the largest contributions to the change in negative symptoms were from the indirect effect mediated through the change in the positive factor score (51%), followed by anxiety/depression (18%), with little contribution made by changes in SAS scores (−2.1%).

Abbreviations: ER, extended release; SAS, Simpson-Angus Rating Scale.